| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.034 | 0.4 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.034 | 0.4 |
| mRNA | BRD4132 | CTRPv2 | pan-cancer | AAC | -0.035 | 0.4 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.068 | 0.4 |
| mRNA | SRT-1720 | CTRPv2 | pan-cancer | AAC | -0.034 | 0.4 |
| mRNA | Docetaxel | CTRPv2 | pan-cancer | AAC | -0.045 | 0.4 |
| mRNA | hyperforin | CTRPv2 | pan-cancer | AAC | 0.035 | 0.4 |
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | 0.032 | 0.4 |
| mRNA | ML006 | CTRPv2 | pan-cancer | AAC | -0.034 | 0.4 |
| mRNA | BRD-K03536150 | CTRPv2 | pan-cancer | AAC | 0.034 | 0.4 |